hadaba halkan waa liiska shirkadaha ugu sareeya ee Biotech ee Germany kuwaas oo lagu saleeyay wadarta dakhliga.
| S / N | Company Name | Wadarta Dakhliga (FY) | Number of Shaqaalaha |
| 1 | Morphosys AG | $401 Milyan | 615 |
| 2 | Brain Biotec Na | $45 Milyan | 279 |
| 3 | Formycon Ag | $42 Milyan | 131 |
| 4 | Biofrontera Ag Na | $37 Milyan | 149 |
| 5 | Vita 34 Ag Na | $25 Milyan | 116 |
| 6 | Hal qayb oo ka mid ah Heidelberg Pharma AG | $10 Milyan | 84 |
| 7 | Medigene Ag Na | $10 Milyan | 121 |
| 8 | 4Sc Ag Inh. | $3 Milyan | 48 |
Morphosys AG
MorphoSys AG waxay ku shaqeysaa sidii shirkad-marxalad-ganacsiyeedka biopharmaceutical. Shirkaddu waxay diiradda saartaa helitaanka, horumarinta, iyo keenista dawooyinka kansarka cusub. MorphoSys waxay u adeegtaa macaamiisha adduunka oo dhan.
Hal qayb oo ka mid ah BRAIN Biotech AG
BRAIN Biotech AG waa shirkad tignoolajiyadeed, taas oo ku hawlan horumarinta iyo ka-ganacsiga bioactives, xeryahooda dabiiciga ah, iyo enzymes la iska leeyahay. Waxay ku shaqeysaa iyada oo loo marayo BioScience iyo qaybaha BioIndustrial.
Qaybta BioScience waxay ka shaqeysaa ensaymes iyo wax qabadyada noolaha; waxayna la shaqeeyaan shuraakada warshadaha. Qaybta BioIndustrial waxay ka shaqaysaa ganacsiyada bioproduct iyo kuwa la isku qurxiyo. Shirkadda waxaa aasaasay Holger Zinke, Jüngen Eck, iyo Hans Günter Gassen Sebtembar 22, 1993 waxayna xarunteedu tahay Zwingenberg, Jarmalka.
Formycon
Formycon waa hormuud, madax-bannaan horumariye oo tayo sare leh dawooyinka biopharmaceutical, gaar ahaan biosimilars. Shirkaddu waxay diiradda saartaa daaweynta indhaha, immunology iyo cudurrada kale ee muhiimka ah, oo daboolaya dhammaan silsiladda qiimaha laga bilaabo horumarinta farsamada ilaa marxaladda bukaan-socodka III iyo sidoo kale diyaarinta dukumiintiyada ogolaanshaha suuq-geynta.
Iyada oo ay la socoto biosimilars-keeda, Formycon waxa ay samaynaysaa gacan weyn oo ku aaddan bixinta bukaanno badan intii suurtagal ah si ay u helaan dawooyin muhiim ah oo la awoodi karo. Formycon hadda waxay leedahay lix biosimilars xagga horumarka. Iyada oo ku saleysan khibradeeda ballaaran ee horumarinta dawooyinka biopharmaceutical, shirkaddu waxay sidoo kale ka shaqeyneysaa horumarinta daawada COVID-19 FYB207.
Biofrontera Ag Na
Biofrontera AG waa shirkad biopharmaceutical ah oo ku takhasustay horumarinta iyo iibinta dawooyinka maqaarka iyo waxyaalaha la isku qurxiyo. Shirkadda fadhigeedu yahay Leverkusen waxay horumarisaa oo suuq geysaa alaabooyin cusub oo loogu talagalay daawaynta, ilaalinta iyo daryeelka maqaarka.
Alaabooyinkeeda muhiimka ah waxaa ka mid ah Ameluz®, oo ah daawo dhakhtar loo qoray oo loogu talagalay daawaynta kansarka maqaarka ee aan melanoma ahayn iyo horudhacyadeeda. Ameluz® waxaa lagu suuq geyn jiray Midowga Yurub tan iyo 2012 iyo gudaha Mareykanka tan iyo Maajo 2016. Yurub dhexdeeda, shirkaddu waxay sidoo kale suuq geyneysaa Belixos® dermocosmetic series, oo ah badeecad daryeel gaar ah oo maqaarka dhaawacan. Biofrontera waa mid ka mid ah Jarmal yar shirkadda dawooyinka si aad u hesho ogolaansho dhexe oo Yurub ah iyo Maraykanka ee dawada lagu sameeyay guriga. Kooxda Biofrontera waxaa la aasaasay 1997 waxayna ku taxan yihiin Isweydaarsiga saamiyada ee Frankfurt (Prime Standard).
Vita 34 Ag Na
Waxaa Leipzig lagu aasaasay 1997 oo ah dhiiggii xudunta gaarka ah ee ugu horreysay bangiga Yurub gudaheeda, Vita 34 waa alaab-qeybiye buuxa oo kaydinta cryo waxayna siisaa saadka si ay u ururiyaan dhiigga, diyaarinta iyo kaydinta unugyada asliga ah ee dhiigga xudunta iyo unugyada.
Unugyada stem waa agab il qiimo leh oo loogu talagalay daawaynta unugyada caafimaadka. Waxay ku nool yihiin heerkul ka yar 180 darajo Celsius si ay awood ugu yeeshaan inay ku dabaqaan xadka daawaynta, marka loo baahdo. In ka badan 230.000 oo macaamiil ah oo ka socda Jarmalka iyo 20 waddan oo kale ayaa hore u furay kaydka unugyada asliga ah ee Vita 34, sidaas darteedna u bixiya caafimaadka carruurtooda.
Hal qayb oo ka mid ah Heidelberg Pharma AG
Heidelberg Pharma AG waa shirkad biopharmaceutical ah oo ka shaqeysa arrimaha kansarka. Shirkaddu waxay diiradda saaraysaa horumarinta Antibody Drug Conjugates (ADCs) ee daaweynta cudurrada oncological. Heidelberg Pharma waxa loogu yeero ATACs waa ADC-yada ku saleysan tignoolajiyada ATAC ee u adeegsata Amanitin walxo firfircoon. Habka bayoolojiga ee ficilka sunta Amanitin waxay u taagan tahay mabda'a daweynta cusub.
Qalabkan lahaanshaha ayaa loo dabaqay si loo horumariyo ATAC-yada daweynta ee Shirkadda iyo iskaashiga dhinac saddexaad si loo abuuro musharaxiin ATAC kala duwan. Musharaxa hogaanka lahaanshaha HDP-101 waa BCMA-ATAC ee myeloma badan. Musharrixiinta horumarineed ee dheeraadka ah waa HDP-102, CD37 ATAC oo loogu talagalay lymphoma non-Hodgkin iyo HDP-103, PSMA ATAC ee kansarka qanjirka 'prostate' ee u adkaysta.
Shirkadda iyo sidoo kale qaybteeda Heidelberg Pharma Research GmbH waxay ku taal Ladenburg oo u dhow Heidelberg ee Jarmalka. Waxaa la aasaasay bishii Sebtembar 1997 iyada oo ah Wilex Biotechnology GmbH ee Munich waxaana loo beddelay WILEX AG 2000. 2011, hoosaad Heidelberg Pharma Research GmbH waa la helay dib u habeyn ka dib, xafiiska diiwaangashan ee WILEX AG waxaa laga soo raray Munich ilaa Ladenburg iyo Magaca Shirkadda waxaa loo beddelay Heidelberg Pharma AG.
Heidelberg Pharma GmbH waxaa hadda loo magacaabay Heidelberg Pharma Research GmbH. Heidelberg Pharma AG waxay ku taxan tahay Sarrifka Suuqa saamiyada Frankfurt ee Suuqa Nidaamsanaansan / Prime Standard.
